Backgrounds/Aims: Metastatic cancer of pancreas is rarely resectable. Pancreaticoduodenectomy carries high risks of morbidities and mortalities that it is rarely performed for metastatic cancer. In this study, the clinical features and outcomes of metastatic cancer of pancreas after pancreaticoduodenectomy were reviewed and analyzed. Methods: We retrospectively reviewed patients who underwent pancreaticoduodectomy from January 2000 to December 2012 in Samsung Medical Center. A total of 1045 patients were enrolled in this study. Inclusion criteria were patients who had metachronous lesions with tumors histologically confirmed as metastatic cancer. However, patients with tumors directly invaded pancreas head, bile duct, and duodenum were excluded from this study. Finally, a total of 12 patients who underwent pancreaticoduodenectomy due to metastatic cancer were used in this study. Clinicopathologic features and perioperative data of these 12 patients were retrospectively reviewed. Results: The 12 patients included 6 females and 6 males who had metastatic lesions at pancreas head, duodenum 2nd-3rd portion, and distal common bile duct. The mean age of patients was 62.7 years old at the time of pancreaticoduodenectomy. The interval between the time of the first operation for primary cancer and pancreaticoduodenectomy was 67.7 months. The mean survival time after pancreaticoduodectomy was 38.6 months (range, 12 to 119 months). There was no fatal complication after the surgery. 
INTRODUCTION
Recently, the number of pancreaticoduodenectomy has increased because early surgical treatment of patients has become possible due to the development in diagnostic technologies for cancer. The development of medical technologies and equipment as well as accumulated experience have gradually reduced the incidence of complications and mortality associated with pancreaticoduodenectomy. 1, 2 However, in many studies about surgical treatment of metastatic cancer at pancreatic head, bile duct, and ampulla of Vater, prognosis and the survival rates are poor and controversial. Renal cell carcinoma and advanced gastric, lung, and breast cancer are known to be primary cancers that are readily to metastasize to common bile duct and pancreas. In particular, surgical treatment of many patients with metastatic cancer from these primary cancers is impossible due to their aggressive characteristics. Recently, regular follow-up and development in the diagnosis of metastasis and recurrences after treatment of primary tumor (surgery, chemotherapy or radiation therapy) have made it possible to diagnose any recurrence or metastasis of the cancer early.
Consequently, the resectability of these secondary tumors is increasing along with surgical treatment improvements. [3] [4] [5] The objectives of this study were to examine patients requiring pancreaticoduodenectomy of peri-ampulla of Vater area metastasis (pancreatic head, common bile duct, duodenum, ampulla of Vater) from primary tumor and to (Table 2) .
MATERIALS AND METHODS
Of the 12 patients, 7 had specific symptoms when they were diagnosed with metastasis; the other 5 were diagnosed through regular follow-ups. Of the 7 patients, symptoms included jaundice (n=3), abdominal pain (n=2), and general weakness (n=2). There was no statistically sig- Table   3 ).
No mortality due to surgery occurred. In postoperative complications, one patient suffered from ileus and one showed fluid collection in the operative site. They were discharged after improvements with conservative treatment.
Severe complications such as pancreatic leakage or pseudoaneurysm were not observed.
DISCUSSION
Pancreaticoduodenectomy of metastatic cancer excluding periampullary cancer is rare. In the past, this surgery was technically complex and difficult to deliver benefits to patients. Patients usually underwent other treatments such as chemotherapy or radiotherapy when metastatic cancer was found. Moreover, surgeries are frequently difficult because the pancreatic metastasis is often accompanied by metastases to other organs. 6 Although the efficacy of pancreaticoduodenectomy for metastatic tumors has not been clearly established, it has been confirmed in several studies that the prognosis could be improved through surgical treatment in patients with primary renal cell carcinoma metastasis to the pancreatic area. 7, 8 In the case of renal cell carcinoma, recurrence or metastasis to lung, liver, and bone is up to 20-30%, with metastasis to pancreatic sites less common. In one case of renal cell carcinoma of the 12 patients in our study, liver and lung metastases were detected after pancreaticoduodenectomy. Thus, differentiation from the primary tumor and histological identification is necessary before the surgical treatment.
When we analyzed the interval between the primary treatment and pancreaticoduodenectomy, there was no significant relationship between the survival period and the time metastatic cancer was detected. When metastatic cancer was detected more than 5 years after the primary operation, the survival time was 51.5 months. When metastatic cancer was detected less than 5 years after the primary operation, the survival time was 48.0 months (p=0.324).
In this study, because the population had only 12 patients, there was no statistically significant difference between many variables, such as survival period and survival rate.
However, our results did show that the survival rate after pancreaticoduodenectomy was affected by the type of primary tumor. In the case of renal cell carcinoma and colorectal cancer, the average survival period after pancreaticoduodenectomy was 63.7 months, longer than other primary tumor patients (mean 29.6 months). This is consistent with other studies. 9, 10 Therefore, when surgical treatment of the primary tumor and metastatic tumor is possible, the prognosis of patients can be improved. 
